A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : PDE5 / phosphodiesterase type 5 inhibitors

[Related PubMed/MEDLINE]
Total Number of Papers: 24
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   PDE5  (>> Co-occurring Abbreviation)
Long Form:   phosphodiesterase type 5 inhibitors
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2021 Exploring the potentials of some compounds from Garcinia kola seeds towards identification of novel PDE-5 inhibitors in erectile dysfunction therapy. ED
2018 Simulation Strategies for Characterizing Phosphodiesterase-5 Inhibitors in Botanical Dietary Supplements. BDSs, DFT, DS, PC, SERS, SPR, TLC
2016 Development and evaluation of an immunochromatographic strip for rapid screening of sildenafil-type compounds as illegal additives in functional foods. ELISA, IC
2016 Erectile Dysfunction Medication Use in Veterans Eligible for Medicare Part D. ED, VA
2014 Effect of chronic administration of PDE5 combined with glycemic control on erectile function in streptozotocin-induced diabetic rats. DM-I
2014 Icariin combined with breviscapine improves the erectile function of spontaneously hypertensive rats. eNOS, nNOS, NO, SHR, WKY
2013 Inhibition of phosphodiesterase 4 enhances clitoral and vaginal blood flow responses to dorsal clitoral nerve stimulation or PGE1 in anesthetized female rats. cAMP, DCN, L-NNA, MAP, PDE4, PGE1, TPU
2013 Which is first? The controversial issue of precedence in the treatment of male sexual dysfunctions. ED, MSD, PE
2013 [Evaluation of the management of erectile and ejaculatory dysfunction in a series of 90 patients with spinal cord injuries]. CMI
10  2012 A survey on illegal and counterfeit medicines for the treatment of erectile dysfunctions in Italy. ---
11  2012 Delay in seeking medical help in patients with new-onset erectile dysfunction remained high over and despite the PDE5 era--an ecological study. CCI, DSH, ED, IIEF-EF
12  2012 Dropout in the treatment of erectile dysfunction with PDE5: a study on predictors and a qualitative analysis of reasons for discontinuation. ED
13  2012 Erectile function outcome after bilateral nerve sparing radical prostatectomy: which patients may be left untreated? BNSRP, CCI, ED, EF, IIEF
14  2012 Exploring the association between erectile rigidity and treatment adherence with sildenafil. ED, EF, EHS, EOT, IIEF
15  2011 Phosphodiesterase type 5 expression in human and rat lower urinary tract tissues and the effect of tadalafil on prostate gland oxygenation in spontaneously hypertensive rats. ETB, HIF-1alpha, LUT, PDE5i, SHR, WKY
16  2011 Phosphodiesterase type 5 inhibitor abuse: a critical review. FDA, VIPPS
17  2009 Phosphodiesterase type 5 inhibitors and female sexual response: faulty protocols or paradigms? ---
18  2009 Post-radical prostatectomy pharmacological penile rehabilitation: practice patterns among the international society for sexual medicine practitioners. ISSM, RP
19  2009 Tadalafil for the treatment of pulmonary arterial hypertension. PAH
20  2009 The influence of testosterone combined with a PDE5-inhibitor on cognitive, affective, and physiological sexual functioning in women suffering from sexual dysfunction. ---
21  2007 [Sexual activity and cardiovascular risk]. MI, PTCA
22  2006 PDE5 inhibitors: are there differences? ED
23  2005 Evidence for contamination of herbal erectile dysfunction products with phosphodiesterase type 5 inhibitors. ---
24  2002 Selective phosphodiesterase type 5 inhibition using tadalafil for the treatment of erectile dysfunction. ED